zilongwang/ReadingBank huggingface dataset:
Madelin Siedler American Gastroenterology Association, USA Health communication (act as public representative) Holger Schunemann Department of Health Research Methods, Evidence and Impact, Canada RIGHT, Practice Guideline Development, GRADE Nancy Santesso Department of Health Research Methods, Evidence and Impact, Canada Patient Version of Guideline Development, GRADE Ana Marušić University of Split School of Medicine, Croatia EQUATOR Network, Croatia RIGHT, Clinical Practice Guideline Development Susan Norris WHO Guidelines Review Committee, Switzerland RIGHT, Practice Guideline Development and Review Janne Estill Institute of Global Health, University of Geneva, Switzerland Epidemiology, mathematical models for disease progression and transmission Elie Akl American University of Beirut Medical Centre, Lebanon RIGHT, Public health and health policy Edwin Chan Shih-Yen Office of Clinical Sciences, Duke-NUS Graduate Medical School, Singapore RIGHT, Clinical decision-making Claire Glenton Cochrane Norway, Norwegian Institute of Public Health, Norway Implementation research and systematic review Joey Kwong National Center for Child Health and Development; Cochrane Gynaecological Cancer Review Group, China Cochrane Systematic Review Sarah Louise Barber WHO Kobe Centre, Japan RIGHT, economic evaluation, quality of care assessments Akiko Okumura Medical Information Network Distribution Service (MINDS) Guideline Centre, Japan Practice guideline development MYEONG SOO Lee Korea Institute of Oriental Medicine, Korea Systematic reviews and clinical trials Suodi Zhai Peking University Third Hospital, China Pharmacy Department and Clinical Practice Guideline Development Hongcai Shang Tianjin University of Traditional Medicine, China RIGHT, Evidence-based Medicine and PVG Development Mingming Zhang Chinese Cochrane Centre, China Patient involvement and patient safety (act as public representative) Yuanyuan Zhang Lanzhou University, China Humanities & social sciences, education (act as public representative)
Record after emergence is complete and give the approximate numbers of plants per metre row for the extreme values used. EARLY VIGOUR (1-9) 1 = very weak 9 = very vigorous This should be recorded soon after full emergence. Record also the weediness and predominant weeds present at this time. GRAZING DAMAGE (1-9) 1 = all plants severely damaged 9 = no plants damaged Indicate the cause of damage and advise the Technical Manager by e-mail what action has been taken to minimise further damage. FLOWERING (1-9) 1 = very late 9 = very early One record is normally sufficient. Please also estimate the date of full flowering for the earliest control variety. LODGING (1-9) 1 = completely lodged 9 = no lodging The aim of this score is to describe the canopy structure at harvest. Please note that because of the nature of lodging in rape plots, a score of 5 can imply either half the plot area completely flat or the whole plot leaning at 45 degrees. PLANT HEIGHT (CM) Record average plot height at the end of flowering before leaning or lodging takes place. If lodging has occurred, choose a representative area of the plot, lift a number of plants against the measuring pole and record an average height. MATURITY (1-9) 1 = very late 9 = very early Maturity can only be judged by opening a number of pods along the length of the plot to assess seed colour. Pod colour does not give a reliable guide. Avoid unrepresentative areas of the plot when making assessments, for example, localised disease infections. YIELD (KG) and DRY MATTER% Obligatory from yield plots. Plot dimensions Plot length The plot length harvested in metres
Protocol Submission Checklist Protocol Title: Submitter: Date: Mandatory documents for all IRB new submissions (exceptions noted): Leave the submitter check box blank if the section is not applicable. Submitter Check Box RSPP Office Use Only Written administrative acknowledgment from Aurora Research Institute Research Certification for each Investigator/Key Personnel must be on file with the IRB () OR NIH Tutorial (acceptable for exempt submissions only) (Log in here: ) Conflict of Interest completed using COI-Smart (Log in here: ) All Investigators/Key Personnel conducting any research activities (as delegated by the Principal Investigator) are required to comply with Aurora IRB policy GA 104. Submission Form with Principal Investigator signature (electronic via .pdf) Complete protocol (either from sponsor or written by investigator) Indicate Version/Date: (N/A for Exempt submissions) Grant application when Aurora is the awardee institution (N/A for Exempt submissions) PI’s current CV (N/A for Exempt submissions or when requesting waiver of informed consent) Informed consent document using Aurora IRB’s recommended template language (Word document) OR (When applicable) Information sheet (Word document) (When applicable) Sponsor’s sample informed consent document (N/A for Exempt and Medical Record Submissions) Delegation of Authority log The IRB office requires a copy of the DOA log signed by the PI at the time of submission, but does not require the signatures/initials of each delegate for the IRB file. However, the site must maintain properly executed original logs for the duration of the study and have them available upon request. (If applicable for protocol; N/A for Exempt submissions) Investigator’s Brochure, Package Insert, or Device Operator’s Manual Indicate Version/Date: (If applicable to protocol) Data collection tool or case report forms (If applicable to protocol) All materials to be seen by subject (recruitment materials, diaries, information cards, etc.) (If applicable to protocol) Surveys, questionnaires (If applicable to protocol) Form SC 502A for Preparatory to Research Activities
Method of implementing the allocation sequence Aim: to describe how the allocation sequence will be run in the study. Successful randomisation in practice depends on two interrelated aspects: 1) generation of an unpredictable allocation sequence and 2) concealment of that sequence until assignment irreversibly occurs. Protocols should describe: the system to use be used e.g. a web based randomisation/treatment allocation system who will access this at each site how the allocation will be documented e.g. will the system provide an immediate allocation with a confirmatory email who else will be provided with a copy of the treatment allocation or randomisation number etc. how will randomisation codes be accessed out-of-hours or in an emergency Blinding Aim: to describe the blinding process to avoid bias in detail. If blinding is not to be used then justification should be provided. The protocol should explicitly describe: who will be blinded to intervention groups including: study participants care providers outcome assessors A full description is essential and ambiguous terminology such as “single blind” or “double blind” should not be used. the comparability of blinded interventions e.g. similarities in appearance, use of specific flavours to mask a distinctive taste the timing of final unblinding of all study participants (e.g., after the creation of a locked analysis data set) any strategies to reduce the potential for unblinding such as prestudy testing of blinding procedures. when blinding of study participants and care providers is not possible because of obvious differences between the interventions, blinding of the outcome assessors can often still be implemented. It may also be possible to blind participants or study personnel to the study hypothesis in terms of which intervention is considered active. Unblinding Aim: to provide a clear description of the conditions and procedures for unblinding. The study code should only be broken for valid medical or safety reasons e.g. in the case of a severe adverse event where it is necessary for the investigator or treating health care professional to know which treatment the patient is receiving before the participant can be treated. Subject always to clinical need, where possible, members of the research team should remain blinded. The following information should be inserted into the protocol:
B 1: Shoulder CT arthrogram Indications: internal derangement and contraindication to MRI. Contrast parameters 12 mL 50% diluted iodinated contrast Region of scan AC joint to bottom 1/3 of scapula Scan delay Within 30 minutes of intra-articular contrast admin Detector collimation 16 x 0.75 mm, 64 x 0.6 mm, 128 x 0.6 mm Slice thickness 1.0 or 1.5 mm axials; sagittal and coronal MPR Filming B30f, B60f kernels Comments: B 2: Elbow CT without contrast Indications: fractures, arthritis. Contrast parameters None Region of scan Humeral metaphysis to proximal ulna Scan delay NA Detector collimation 16 x 0.75 mm, 16 x 0.6 mm (64 and 128 slice) Slice thickness 1.0 or 1.5 mm axials; sagittal and coronal MPR Filming U90u kernel
B 12: Lower extremity CT without contrast (Conformis protocol) Indications: knee replacement planning, contraindication to MRI Contrast parameters None. Region of scan 1) Hip: through femoral head only. 2) Knee: top of patella to 3 cm below tibial plateau. 3) Ankle: malleoli through talus. Scan delay None. Detector collimation 16 x 0.75 mm, 64 x 0.6 mm, 16 x 0.6 mm (128 slice) Slice thickness 2.5 mm at 2.5 mm intervals. 1.5 mm at 0.5 mm intervals; 1 mm sagittal and coronal reformats. 2.5 mm at 2.5 mm intervals. Filming B70s kernels Comments: Patient positioning: supine, feet first, toes pointing straight up. If contralateral knee has implant, elevate that knee to mitigate artifact. Recommended FOV: 25-30 cm for hip, 20-25 cm for knee, 15-20 cm for ankle.
Contrast parameters 125mL @ 2.5 mL/sec; OR 100 mL @ 2.5 mL/sec, with 30 mL saline flush. No contrast for trauma evaluation Region of scan 1) Tumors: hard palate to sternal notch 2) Cord paralysis: sella to carina 3) Trauma: hyoid to sternal notch Scan delay 40 sec Detector collimation 16 x 0.75 mm, 64 x 0.6 mm, 128 x 0.6 mm Slice thickness 3.0 mm axials, with additional 1.5 mm axials through true vocal cords. 1.0 mm thick coronal reformats. Filming B31s kernel; add B70f for trauma cases Comments: Siemens NeckThinSlice package. CPGH-using Care dose and Care KV Radiologist to select level of thin slices through true vocal cords. Optional breathing instructions: Straw-blowing: adducts vocal cords ‘Eee’ phonation: assesses cord paralysis Quiet breathing: abducts vocal cords N 10: Pre- and post-contrast sella CT Indications: pituitary pathology and contraindication to MRI scan. Contrast parameters 1) None 2) 100 mL at 2.5 mL/sec Region of scan Foramen magnum to vertex, angled to avoid orbits. Scan delay 1) NA 2) 60 sec
Principal Investigator (2) [PI at additional sites, etc. as applicable] Insert Name Insert Department Insert Address Insert Phone # Insert Email [If applicable] Insert the Name of the Sponsor or Sponsor Investigator Insert Department Name Insert Address Insert Phone Number Email Address Fax Number NIH Grant Number Include NIH grant number if applicable Investigational Product: [If applicable] Insert Investigational Product Name Protocol Number: [If applicable] IRB Number: Insert Protocol Number- As assigned by ACC, sponsor, etc. as applicable Assigned by the IRB. Will not be available at the time of submission. IND/ IDE Number: [If applicable] Insert IND Number or IDE number if applicable. This number will be assigned by the FDA. If not available write pending ClinicalTrials.gov Number If applicable Include the National Clinical Trial (NCT) Number assigned once the trial is registered on the ClinicalTrials.gov website. Initial version [Date] adopt a version control numerical system. Suggest use 0.1, 0.2 for draft versions and 1.0 and 2.0 etc after protocol ahs been finalized. Then stick with numbering convention Amended [Date] Amended [Date] Table of Contents
Clinical Intervention Study Protocol Template PREFACE The Clinical Intervention Study Protocol Template is a suggested format for clinical trials sponsored by the National Center for Complementary and Integrative Health (NCCIH). Investigators are encouraged to use this format, as appropriate, when developing protocols for their studies. Large multi-site observational studies will also benefit from this protocol template. Note that instructions and explanatory text are indicated by italics and should be replaced in your protocol with appropriate text. Section headings and template text formatted in regular type should be included in your protocol document as provided in the template. The goal of this template is to provide a general format applicable to all single- and multicenter clinical intervention trials (e.g., drug, surgery, behavioral, nutritional, device, etc). As you can see the version number and date are on the bottom of each page. When making changes to an approved and “final” protocol, please provide a summary of the changes, with the date, at the front of the protocol.
6.1 Schedule of Evaluations Assessment Screening: Visit-1 to Day -1) Baseline, Enrollment, Randomization: Visit 1 (Day 0) Treatment Visit 2 (W1) Treatment Visit 3 (W2) Treatment Visit 4 (W3) Treatment Visit 5 (W4) Treatment Visit 6 (W5) Followup: Final Visit (W10) Informed Consent Form X Demographics X X DXA X X Medical History X General Physical Examination X X X X X Current Medications X X Blood Chemistries X X X X X Hematology X X X X X Urine Analysis X X X X X Vital Signs X X X X X X X X Inclusion/Exclusion Criteria X Enrollment/Randomization X Treatment Administration Form X X X X X Concomitant Medications X X X X X X X Adverse Events X X X X X X X
No. Town Hospital Local PI 1 Sheffield Royal Hallamshire Hospital Ms Lynda Wyld 2 Leicester Glenfield Hospital Ms Anne Stotter 4 Whiston St Helen’s and Knowsley NHS Trust Professor Riccardo Audisio 5 Hull Castle Hill Hospital Mr Peter Kneeshaw 6 Dartford Darent Valley Hospital Ms Seema Seetharam 7 Newcastle Royal Victoria Infirmary Mr Richard Bliss and Mr Andy Griffiths and Professor Tom Lennard 8 Weston Super Mare Weston General Hospital Mr Nick Gallegos 9 Chesterfield Chesterfield Royal Infirmary Mr Steve Holt 10 Coventry University Hospital Mr Martin Lee 11 Cardiff University Hospital of Wales Professor Robert Mansel and Professor Helen Sweetland 12 Bristol Frenchay Hospital Mr Mike Shere 13 Milton Keynes Milton Keynes NHS Trust Ms Amanda Taylor 14 Southend Southend Breast Unit Mr Neil Rothnie 15 Plymouth Derriford Hospital Mr Roger Watkins 16 Liverpool Liverpool University Hospital Mr Chris Holcombe 17 Derby Derby Royal Infirmary Mr KL Cheung 18 Grantham Grantham and District Mr AK Modi 19 Scarborough Scarborough Hospital Sister Alison Ames, (Oncology Research Nurse) 20 Wakefield Pinderfields Hospital Mr Jit Parmar 21 Reading Royal Berkshire Hospital Mr Stephen Courtney 22 Doncaster Doncaster Royal Infirmary Ms Clare Rogers 23 York York Royal Infirmary Ms Rana Nasr 24 London Guy’s Hospital Mr Michael Douek 25 Leeds St James Hospital Mr Kieran Horgan 26 Bristol University Hospitals Bristol Mr Zen Rayter 27 Rotherham Rotherham District General Mr Inder Kumar 28 Barnsley Barnsley District General Hospital Ms Julia Dicks 29 Southport Southport Hospital Mr Ramsay Cutress 30 Scunthorpe Scunthorpe General Hospital Mr Vijh Rajesh
[Optional: Insert any additional role(s) and responsibilities that apply to this SPG] PROCEDURE Protocol Development [Describe the process used to draft a protocol] Protocol Finalization including IRB approval [Describe the process used to review, revise, and approve a protocol including IRB approvals] Protocol Maintenance [Describe the process for initiating and writing an amendment to the protocol] [Describe the process used to review, revise and approve a protocol amendment including IRB approvals] [Describe the process for version control of the protocol] [Describe the process for storing and accessing current, and retired versions of an approved protocol] Additional Procedures N/A [Optional: Insert any additional relevant procedures. Provide enough detail to ensure the procedure is consistently carried out, without providing so much detail that violations occur due to normal or expected variations in the work.] REFERENCES Food and Drug Administration (FDA): http://www.fda.gov/Drugs/default.htm FDA Title 21 CFR 312 Subchapter D - Investigational New Drug Application FDA Title 21 CFR 312.23 - IND content and format
PROTOCOL DEVIATION TRACKING LOG Principal Investigator: Site #: IRB#: Protocol #: Study Title: Sponsor: Subject ID Date of Deviation Date Known to Investigator Description of Deviation/Exception Major/ Minor Subject Harmed Action Taken/CAPA Date Sponsored Notified Date of Sponsor Acknowledgement Date of IRB Notification/ Submission PI Signature/ Date Comments 1 2 3 4 5 6
Protocol Deviation Tracking Log Protocol ID/Number: Site Name: Protocol Title: Principal Investigator: Page number [1]: Ref No. Subject ID Date of Deviation Date Identified Deviation Description Dev. Type [2] Resulted in AE? Did Subject Continue in Study? Meets IRB Reporting Req. (Yes/No) IRB Reporting Date 1 2 3 4 5 6 7 Investigator Signature: Date:
Protocol Deviation Tracking Log Protocol ID/Number: Site Name/Number: Protocol Title (Abbreviated): Principal Investigator: Page number [1]: Ref No. Subject ID Date of Deviation Date Identified Deviation Description Dev. Type [2] Resulted in AE? Did Subject Continue in Study? Meets IRB Reporting Req. (Yes/No) IRB Reporting Date 1 2 3 4 5 6 7 Investigator Signature: Date:
Let students talk with a partner to check understanding. What focus questions can be used to guide discussions? What information about student understanding/confusion did the discussions reveal? Monitor students’ understanding. Where are the places in the text where students are likely to be confused? How I will know when students are confused? (e.g., annotations, partner discussions) How might/did I respond to student misconceptions or confusion? Use shared reading and model thinking aloud.* At what points during the think aloud will I model the use of prior knowledge? At what points during the think aloud will I model how to solve an unknown word? At what points during the think aloud will I model how to apply strategies when meaning was breaking down? At what points during the think aloud will I model how to use other strategies good readers use to make meaning?
Introduction 1. Roles and Responsibilities 2. Procedures within the London Borough of Bromley 3. Suspension 4. Initial Considerations by the LADO 5. Strategy Meetings 6. Action if criminal investigation concludes with no prosecution or conviction 7. Sharing information for disciplinary purposes 8. Resignations and Compromise agreements 9. Record Keeping 10. Support 11. Timescales 12. Monitoring progress 13. Definitions of allegation outcomes 14. Unsubstantiated, false or malicious allegations 15. Substantiated Allegations 16. Learning lessons 17. Allegation Process Flowchart 18. Useful contacts Introduction
Contents Page Number Definitions 4-5 Introduction 5 Identification Of Harm 6 Large Scale Inquiry Meeting 6-7 Large Scale Investigation planning meeting 7-8 Large Scale Investigation 9-10 Media Strategy 11 Large Scale Investigation outcome meeting 11-12 Adult Protection Committee 12 Closure 13 Appendix A – Examples Of Identification Of Harm 14-15 Appendix B – Large Scale Investigation Inquiry Meeting agenda 16 Appendix C – Large Scale Investigation Planning Meeting Agenda 17 Appendix D – Large Scale Investigation Outcome Meeting Agenda 18 Appendix E – Process Flowchart 19-20 Appendix F – Notification Guide 21 Appendix G – Monitoring Group – Process And Forms 22-31 Appendix H – Good Practice Tools 32-36 Protocol for Large Scale Investigations of Adults at Risk of Harm
Introduction Where excavations are being undertaken, operatives must have access to good information about the presence of underground services. The identification of underground service hazards cannot be left to chance. This protocol details the actions to be taken in order the safeguard employees and sub-contractors as well as members of the public. It is aimed at defining responsibilities and promoting co-operation and co-ordination between duty holders, including clients, designers, planners, CDMC, contractors and service owners. This protocol should be used in conjunction with the Charter document and the toolkit provided, to assist and provide guidance on the implementation of controls to ensure safety when working near underground services. Stage Actions Duty holders Legislation, ACOP, COP & Guidance Concept and Feasibility Appoint competent adequately resourced designers and/or planners Client CDM MHSW HSWA Competent designers and planners are to be in a position to determine the ; Impact of their designs on the utility apparatus Best available technique for locating and protecting underground services, and Statutory obligations and best practice guidance documents requirements Designer / planner Design and Planning Contact the utility owner to establish the position of their apparatus inclusive of limitations on accuracy of new and older services. Designer / planner NRSWA HSG47 EAW PUWER Provide the designer / planner with up to date, legible plans that Utility Owner
How are members of the ECS team trained on the tools and assessments used by the subrecipients they are assigned? How is observation and feedback other than the end-of-year PQA used and documented? Consultant Notes D=Documentation Note I=Interview Note Findings Program Monitoring Area G: Program Delivery/Early Childhood Specialists G.2 The ISD Program Quality Assessment (PQA) End-of-Year Form A and Form B interviews and observations are scheduled, completed and submitted on time for all classrooms. The ECS reviews results and sets subsequent year goals with appropriate staff. (IM 4.5-4.8) Possible Documentation to Review: Sample of ECS schedules or calendars for End-of-Year PQAs, PQA reports, documentation of annual goals Interview with ECC and ECS team: How and when does the ECC monitor PQA completion? How are the results used ISD-wide, subrecipient-wide and for specific classrooms? Consultant Notes D=Documentation Note I=Interview Note Findings
Program Monitoring Area H: Program Delivery/Continuous Quality Improvement H.2 The ECS gives teaching team relevant feedback and supports the achievement of goals set locally and program-wide throughout the year with professional development, at least three on-site visits and other supports as needed. (IM 4.8) Possible Documentation to Review: Sample ECS position descriptions Local and ISD-wide goals for the current year and following year Documentation of classroom visits other than End-if-Year PQA Professional Development Calendar Interview with ECS team: Describe the flow of the year in terms of supporting continuous quality improvement. What works well and what could be improved?
Pig urine for metabolomics LC-MS analysis (C18, HSS T3) (2017) Chemicals Acetonitril (ACN) (VWR) Formic acid (FA) Glycocholic acid (Glycine-113C) p-chlorophenylalanine Solutions H2O/ACN/ formic acid (95/5/0.1) (950 ml MILLIQ-water added 50 ml acetonitril and 1 ml FA.) ACN/IS: Internal standard solution (concentration: 0.1 mg / mL; final concentration: 0.01 mg / mL). Calculation, see bottom of document. Materials 2 ml Eppendorf tubes Pipettes and pipette tips Centrifuge Intern standards (IS) Glycocholic acid (Glycine-113C) solution in methanol (final concentration of 1 mg/ml) p-chlorophenylalanine solution in 2 % formic acid (final concentration 1 mg/ml) Sample preparation 180 μl urine is mixed with 20 μl ACN/IS Blank sample: H2O treated as a sample QC sample: 20 μl pool of each urine sample is treated as a normal sample Blind: 0.1% FA Protein precipitation in the fridge (20 min, 4°C). Centrifugation (10 min, 13,200 rpm, 4°C). The supernatant is transferred to vials with micro inserts (150 μl). Analysis on UHPLC-MS with C18 column (HSS T3) according to LC-MS procedure.
PROTOCOL APPROVAL SHEET TRIAL CODE CT EP02 PROTOCOL TITLE A MULTICENTRE PHASE III TRIAL OF 1,2-OCTANEDIOL AT 5%(W/V) (KINDAPEDTM) COMPARED WITH MALATHION 0.5% (W/V) (DERBAC-M LIQUID) IN THE TREATMENT OF HEAD LICE AUTHOR(S) Author Graeme Scott, PSCR (Signature) (Date) Statistics Section Peter N Lee, P.N Lee Statistics and Computing Ltd. (Signature) (Date) APPROVAL Medical Advisor Dr Veronica Tebbs
5. TRIAL PRODUCTS 5.1 INVESTIGATIONAL KindaPed contains: Active: 1, 2--octanediol at 5% (w/v). Excipients: Propan-2-ol (IPA)/water 20% (v/v); Sodium Dodecyl Sulphate (SDS) 0.64% The product will packed in 100 mL low density polyethylene (LDPE) plastic bottles with an applicator nozzle. 5.2 Derbac-M Liquid contains: Active: Malathion at 0.5% (w/v) Excipients: Methylhydroxybenzoate; Propylhydroxybenzoate; Lanette Wax SX; Potassium Citrate; Citric Acid; Perfume HT 52; Water. The product is packed in 200 mL clear or amber glass bottles with polyethylene caps. 5.3 DOSAGE AND ADMINISTRATION All products supplied in connection with this clinical trial must be used only for this and no other purpose. Treatment will be administered on Days 0 and 7 by research staff, who will not be involved in the assessment of the treated subjects or characterisation of lice found. KindaPed™ KindaPed™ will be applied directly to dry hair. Sufficient product will be applied to thoroughly moisten the hair and scalp. More than one bottle may be used if required (maximum of two bottles). The period of time for which the product will be left in the hair prior to
8 A Help raise resources for the CIMO Trust Fund to enable hiring someone for that. All On going From teleconference of 23 Jan. 2014 12 A Site Managers to send to Rodica picture that are representative of their sites, which would be used for presentations/posters on SPICE Site Managers on-going From teleconference of 19 Dec. 2013 9 A Follow-up on gauge heights (non-DFIR) Rodica Jan 16th 16 A Send Audrey proposals for any terms to be defined all ongoing From teleconference of 24 Oct. 2013 2 A The SPICE report will need to provide feedback on calibration procedures as stated in Geonor manual to inform those using these gauges. Key points: Gauge levelling Compare 3-wire average (requires algorithm from DAT) or individual transducers with calibration load Comparison impacts procedure in manual: if errors more than 0.5%, Geonor recommends correction of A, f0 coefficients Covering of gauge orifice during calibration Rodica In the Final report From teleconference of 20 Sept. 2012 1 A Look at vertical wind profile: compare measurements with observations at different heights John Aug 2013 Attachments: None.
From teleconference of 18 September 2014 From teleconference of 7 August 2014 7 A Finalization of Sodankyla meeting report is still underway. Some presentation summaries are still missing from Antonella, Leena, Niina, Arkady. Antonella, Leena, Niina, Arkady, Isabelle 31 Aug. 2014 11 A Present a Summary of methods implemented at NCAR in support of SPICE; to be demonstrated during next telecon Roy/Andy Next telecon 13 A Provide a tutorial (demo and written) on how to use all features implemented at NCAR, that are expected to be used by Site Managers, and DAT members Roy August 15 A Assess and discuss methods for tying together SoG with event selection; an NCAR or offline? Craig Next telecon From teleconference of 20 February 2014 8 A Help raise resources for the CIMO Trust Fund to enable hiring someone for that. All On going From teleconference of 23 Jan. 2014 12 A Site Managers to send to Rodica picture that are representative of their sites, which would be used for presentations/posters on SPICE Site Managers on-going From teleconference of 19 Dec. 2013 9 A Follow-up on gauge heights (non-DFIR) Rodica Jan 16th 16 A Send Audrey proposals for any terms to be defined all ongoing From teleconference of 24 Oct. 2013
and the assistant project coordinator (Syrian nationality) of the Southern Syria Project. The questionnaires will be piloted in the field with a convenience sample of households during the training to ensure they are understood (see Annex I). The main indicators to be derived are listed in table 2. Indicator Sub objective Source (MSF surveys) Rationale Household variables (Age, gender, living condition. Number of people and size household. Literacy level of head of household. Type of dwelling. Occupation. Household income) 1 23,25 Risk factors for indicators Shelter size (% of population with <3.5m² per person) 1 23,24,25,26 Risk factors for indicators Prevalence of self-reported morbidities (incidence or % of the total population over the past 4 weeks) 2 24,25 Advocacy purposes Non-communicable disease (prevalence per type of NCD, and if care provided) 2 23,24,25,26 Response capacity and operational Main reasons for requiring care (over the past 4 weeks) 2 2 Response capacity and operational Prevalence of vaccination coverage in children (MMR, Polio, DTP) 3 23,24,25,26, 27 Response capacity and operational Health utilization rate (% of the total population who received medical services within 30 days of interview) 4 23,25,26 Response capacity and operational Health care seeking behaviour/access to health care (% of population that did not seek health care when needed, what type of health care) 4 25,26 Response capacity and operational Global acute malnutrition rate (Prevalence of children 6-59 months with Mid-Upper Arm Circumference [MUAC] less than 125mm) 5 24,25 Response capacity and operational War related injuries (% of population affected by war injuries, what type) 6 25,26 Advocacy purposes Surgery (% of people that received surgery and how many are war related) 6 - Response capacity and
ANALYSES references should be “DSMB”; for non-NIH funded studies, refer to the” DMC.” Sample text: When approximately 50% of patients have completed the study through Visit X, an interim analysis for safety will be conducted by an independent data monitoring committee. Serious adverse events will be monitored by the committee on an ongoing basis throughout the study. STATISTICS Primary Analysis Plan Describe plan for analyzing the primary endpoint. Rationale for Number of Subjects BACKGROUND Identify the product to be studied, and describe it briefly. Overview of Non-Clinical Studies Provide a brief summary of the non-clinical data that has clinical significance. Overview of Clinical Studies Provide a brief summary of the clinical data that are relevant to the study. For more detail refer to the Investigator’s Brochure. (or, for approved drugs, to the Prescribing information.
<Insert text> 5.4 5.4.1 <Insert text> 5.4.2 <Insert text> 5.5 <Insert text> 6 STUDY AGENT 6.1 6.1.1 <Insert text> 6.1.2 <Insert text> 6.1.3 <Insert text> 6.1.4 <Insert text> 6.1.5 <Insert text> 6.1.6 <Insert text> 6.1.7 <Insert text> 6.1.8 STUDY AND SCHEDULE OF AND AND CONTROL OF HANDLING ADMINISTRATION OF
<Insert text> 6.1.9 <Insert text> 6.1.10 <Insert text> 6.1.11 <Insert text> 6.2 <Insert text> 7 PROCEDURES 7.1 7.1.1 <Insert text> 7.1.2 <Insert text> 7.2 7.2.1 <Insert text> 7.2.2 <Insert text> 7.2.3 <Insert text> 7.2.4 <Insert text> 7.3 CLINICAL CONSIDERATIONS AND STUDY
7.3.1 <Insert text> 7.3.2 <Insert text> 7.3.3 <Insert text> 7.3.4 <Insert text> 7.3.5 <Insert text> 7.3.7 Procedures <Insert text> <insert text> X <Insert text> 7.4 <Insert text> 7.5 <Insert text> 7.5.1 <Insert text> 7.6 <Insert text>
The PI shall submit on request, a Progress Report to the MS IDREC with a copy to CTRG. Other Ethical Considerations Include any other general and study-specific ethical considerations, e.g. involvement of vulnerable participants. FINANCE AND INSURANCE Funding Describe financing arrangements. Insurance The University of Oxford has a specialist insurance policy in place which would operate in the event of any participant suffering harm as a result of their involvement in the research (Newline Underwriting Management Ltd, at Lloyd’s of London). PUBLICATION POLICY The publication policy should cover authorship, acknowledgements, and review procedures for scientific publications. If there is a department or institution policy, or agreement, the protocol can refer to it. If the study results form part of a Masters or DPhil dissertation, please refer to Departmental policy on publications. Consider describing how study results may be disseminated to study participants. Example: The Investigators will be involved in reviewing drafts of the manuscripts, abstracts, press releases and any other publications arising from the study. Authors will acknowledge that the study was funded by < >. Authorship will be determined in accordance with the ICMJE guidelines and other contributors will be acknowledged. REFERENCES Insert references used in text (preferably numbered, or in alphabetical order of first author). APPENDIX A: STUDY FLOW CHART Optional
Study Title: insert full title including brief reference to the design, disease or condition being studied, and primary objective Internal Reference Number / Short title: This should be assigned by the investigator/department (may be deleted if not required) Med IDREC Ref: Insert Date and Version No: Insert Chief Investigator: Insert name and contact details, including institutional affiliation Investigators: Insert names of key collaborators, including institutional affiliations Sponsor: University of Oxford Funder: Insert details of organisation providing funding Chief Investigator Signature: The approved protocol should be signed by author(s) and/or person(s) authorised to sign the protocol Please declare any potential conflicts of interest. Confidentiality Statement This document contains confidential information that must not be disclosed to anyone other than the authorised individuals from the University of Oxford, the Investigator Team and members of the Medical Sciences Interdisciplinary Research Ethics Committee (Medical Sciences IDREC), unless authorised to do so. TABLE OF CONTENTS To update table of contents (TOC), hover cursor over the table and ‘right click’. Choose ‘update field’, then ‘update entire table’.
method of assignment to study group, adding study arms, visits, etc.). The time point(s) indicated in the schematic should correspond to the time point(s) in Section 1.3, Schedule of Activities, e.g., Visit 1, Day 0; Visit 2, Day 30 ± 7; etc. Example #1 Flow diagram (e.g., randomized controlled trial)
REFERENCES Include a list of relevant literature and citations for all publications referenced in the text of the protocol. Use a consistent, standard, modern format, which might be dependent upon the required format for the anticipated journal for publication (e.g., N Engl J Med, JAMA, etc.). The preferred format is International Committee of Medical Journal Editors (ICMJE). Include citations to product information such as manufacturer’s IB, package insert, and device labeling. Examples:
uniformity (with respect to CAX)? Are range compensators used to vary penetration of beam across the field? Yes/no If so, what material is used? acrylic wax What kind of patient specific beam collimation is used? apertures MLC none Is modulated scanning used for patients on NCI supported clinical trials? Yes/no If modulated scanning is used, how long does it take to irradiate a 10x10x10 cm³ target volume that has a distal depth of 20 cm of water to 1 Gy? minutes For spot scanning for the field above, what is the average and variation in spot size? 16 mm ± 1 mm Over all energies, what are the maximum and minimum spot sizes? max 30 mm min 10 mm *Note: Use these codes to describe methods of range modulation that might be used for protocol patients (may combine codes for accurate description, for example 1 & 2, or 3 & 4): 1. rotating stepped rangeshifter (modulator wheel or propeller) 2. beam current modulation 3. ridge filter 4. energy stacking 5. spot scanning 6. upstream rangeshifter 7. Other (describe) C4. How is dose uniformity over SOBP specified? (e.g. relative to nominal center of modulation, relative to measured center of modulation, relative to average dose within modulated region, etc.) C5. For each beam applicator (cone) available, please supply the shape, maximum field size supported, maximum range, and typical clinical dose rate at maximum field size and maximum range for 6.0 cm of range modulation. Beam Applicator ID Shape (circle, square, other) Max Field Size [cm] Max Range [cm water] Dose Rate [Gy/min]
Name:________________________ Period:______ Protons, Neutrons, and Electrons Practice Worksheet Atomic symbol Atomic number Protons Neutrons Electrons Mass Number Atomic Mass B 6 11 24 31 37 39 89 35 63.5 43 100 Pb 207 102 70 225 227 Mo 53 81 206 100 159 No 261 Tm 170 106 159 22 20.2 19 39 2 2 Ti 49 30 55.8 4 5 16 32 V 28
Observing and Classifying Protozoa Background The name protozoa actually means “first animals”. This name was given because many protozoa share characteristics with animals. However, there are also many that share characteristics with plants. In this lab, you will observe different members of this diverse group. Materials Microscope Clean glass microscope slides Clean cover slips Pipette Live samples of: Amoeba proteus Volvox Euglena gracilis Paramecium caudatum Six other protozoa cultures Background The classification of protozoa is a constantly changing field. Below are listed the five “supergroups” that protozoa are currently classified in and a summary of common characteristics of each. Excavata – Name refers to an “excavated groove” found on one side of the cell. Most excavates are heterotrophic and move with a flagellum. Chromalveolata – Many contain pigments (“chromo”) and membrane bound sacs (“alveolata”) inside their cells. May be autotrophic or heterotrophic. Movement varies. Rhizaria – Name refers to threadlike pseudopods used for movement. Archaeplastida – Group of eukaryotes most closely related to plants. Each contains a form of a chloroplast. Most reproduce sexually. Unikonta – Group of eukaryotes most closely related to animals. All are heterotrophic. The protozoa are very difficult to classify due to their wide variety. Summarize each of the following groups of protists in the table below: Excavata “Excavated groove” Chromalveolata “Colored with membrane sacs” Rhizaria “Thread-like pseudopods” “Plants and relatives” “Animals and relatives”
The Amoeba – Scoring Guide 1. c (3 choices) 2. b 3. d 4. b (3 choices) 5. d 6. a 7. b 8. a (2 choices) 9. c 10. b 11. b (3 choices) 12. d 13. d Scoring Guide 13-14 – 3 11-12 – 2.5 8-10 – 2 5-7 – 1.5 3-4 – 1 1-2 – .5 0 – 0
Exercise Name: [Insert exercise name] Exercise Date: [Insert exercise date] Organization/Jurisdiction: [Insert organization or jurisdiction] Venue: [Insert venue name] Protection Exercise Objective: [Insert exercise objective] Core Capability: Cybersecurity Protect against damage to, the unauthorized use of, and/or the exploitation of (and, if needed, the restoration of) electronic communications systems and services (and the information contained therein). Organizational Capability Target 1: [Insert customized target based on plans and assessments] Critical Task: [Insert task from frameworks, plans, or SOPs] Critical Task: [Insert task from frameworks, plans, or SOPs] Critical Task: [Insert task from frameworks, plans, or SOPs] Critical Task: [Insert task from frameworks, plans, or SOPs] Source(s): [Insert name of plan, policy, procedure, or reference] Organizational Capability Target 2: [Insert customized target based on plans and assessments] Critical Task: [Insert task from frameworks, plans, or SOPs] Critical Task: [Insert task from frameworks, plans, or SOPs] Critical Task: [Insert task from frameworks, plans, or SOPs] Critical Task: [Insert task from frameworks, plans, or SOPs] Source(s): [Insert name of plan, policy, procedure, or reference] Organizational Capability Target 3: [Insert customized target based on plans and assessments] Critical Task: [Insert task from frameworks, plans, or SOPs] Critical Task: [Insert task from frameworks, plans, or SOPs] Critical Task: [Insert task from frameworks, plans, or SOPs] Critical Task: [Insert task from frameworks, plans, or SOPs] Source(s): [Insert name of plan, policy, procedure, or reference]
Organizational Capability Target Associated Critical Tasks Observation Notes and Explanation of Rating Target Rating [Insert Organizational Capability Target 1 from page 1] [Insert Organizational Capability Target 1 Critical Tasks from page 1] [Insert Organizational Capability Target 2 from page 1] [Insert Organizational Capability Target 2 Critical Tasks from page 1] [Insert Organizational Capability Target 3 from page 1] [Insert Organizational Capability Target 3 Critical Tasks from page 1] Final Core Capability Rating Ratings Key P – Performed without Challenges S – Performed with Some Challenges M – Performed with Major Challenges U – Unable to be Performed Evaluator Name Evaluator E-mail Phone
Summer vacations and summer reading programs are just distant memories now. School is back in session, and now it’s time to restock the library shelves! Join us for our fall Teen Book Buzz webcast to be sure you have the latest releases ready for your teen readers. September 30 M This course provides a brief introduction to the Worldcat.org platform and illustrates how libraries can help patrons derive maximum advantage from the service. This class will cover the role of your board, why board members may be reluctant to fundraise, how to overcome these concerns, and ways the board can participate in fundraising activities. October 7 Using Drupal to Build Library Websites 6-week eCourse In this introductory eCourse Varnum will guide participants in building a functional library website using Drupal. Test websites will be hosted on a server for six months after the eCourse, facilitating additional learning. This eCourse will focus on Drupal 7, while highlighting what is still applicable to Drupal 6. Ken Varnum has been the Web Systems Manager at the University of Michigan Library since 2007, a position that involves all aspects of the libraries' websites. . October 7-11 National Library Communications Week Kathleen McCallick and the association management staff of ALCOP is working on a week-long celebration to honor and bring attention to the work of library communications professionals throughout North America. We are calling it National Library Communications Week and it will take place October 7-11. A grand media campaign is being planned which will include feature stories in the major library publications, video presentations, and podcasts, all showcasing the work of library
Workshops September+ 2013 Please check the times listed as you may be in a different time zone. Workshop time may be found on the registration site. Most of these are free but a few do charge fees. Want to attend a workshop that requires a fee? Don't forget to look into Continuing Education Assistance from the Office of Commonwealth Libraries. You may be eligible for up to $600. To register for the webinars/workshops below, either click the heading or the provided link. Also check the for additional offerings. Miss a webinar? Many providers archive the recording. Check out . September 1 is a 4 week introductory course with a recommended total of 8-12 hours participation time. Registration opens on 19th August 2013 and the course starts on 1st September 2013. There are no fees for taking the course and successful participants will be awarded a course completion badge that they can add to their . September 3-4 National Archives Virtual Genealogy Fair For the first time ever, the National Archives will host a virtual Genealogy Fair via webcast using the Internet. This two-day program will showcase tips and techniques for using Federal records at the National Archives for genealogy research. Lectures are designed for experienced genealogy professionals and novices alike. Lecture topics include Native American and African American history, immigration, Civil War pensions, U.S. Colored Troops, and Navy Deck logs. “Help! I’m Stuck” Call-In Consultation: National Archives staff will be available to answer research questions during the Fair. WHEN: Tuesday and Wednesday, September 3–4, 10 a.m.–4 p.m. EST WHO: Speakers include genealogy experts from the National Archives and U.S. Citizen and Immigration Services.
*Access *Outreach and exhibition *Reaching and documenting underrepresented groups Speakers: George Blood President, George Blood Audio and Video Charles Hardy III Professor of History, West Chester University Bertram Lyons Folklife Specialist/Digital Assets Manager, Library of Congress American Folklife Center Joyce Hill Stoner Edward F. and Elizabeth Goodman Rosenberg Professor of Material Culture, University of Delaware (UD) Paintings Conservator, Winterthur/UD Program in Art Conservation Director, UD Preservation Studies Doctoral Program Sady Sullivan Director of Oral History, Brooklyn Historical Society Program Fees: $95 CCAHA members $110 Non-members More information about this program and online registration is available at . For information on additional educational opportunities, visit December PubMed for Librarians The NLM Training Center is offering online classes beginning in December 2013. Check out to see the individual course listings and to register. NOTE: recordings of the most recent classes are available: /
15541 AVE. TUSTIN, CA 92780 788-0900 206 & 220 (714) 862-1008 & CREDIT@PROVENZAFLOORS.COM *** LEGAL BUSINESS NAME: (LIST ALL TRADE NAMES, DBA’S DIVISIONS OR SUBSIDIARIES) MAILING ADDRESS: CITY: STATE: ZIP CODE: SHIP TO ADDRESS: CITY: STATE: ZIP CODE: BUSINESS PHONE: FAX: WEBSITE: LLC: HST 2 CONTACTS): EMAIL(S): BANK NAME: ACCOUNT NUMBER: BANK ADDRESS: CITY: STATE: ZIP CODE: CONTACT: PHONE FAX PLEASE DO NOT USE SHAW OR MOHAWK) COMPANY NAME: CONTACT: ACCT #: ADDRESS: CITY STATE ZIP CODE: PHONE: EMAIL:
Coupon Good For Renting the principal’s chair for the day Coupon Good For Taking off your shoes in class Coupon Good For One free answer on a homework assignment Coupon Good For Being assistant principal for 15 minutes Coupon Good For Working in the score booth at the next game Coupon Good For BBABG Buying back a bad grade (chance to redo an assignment) Coupon Good For Seeing an embarrassing photo of the principal when he/she was a little kid Coupon Good For One free hot chocolate with the principal
A stranger nearby is better It is better to protect yourself with your friends It is better to live one day as a lion 2. PROVERB ENDINGS than one. United States than a big fish in the ocean. Ireland than never United States than not to begin at all. England than sorry United States than to get lost once. Denmark
than wealth. Ireland than one enemy inside the tent. Afghanistan than to be in bad company. Germany than two books. Russia than rich and hated. Germany than to stand on the water’s edge and pray for fish. China than to say yes and not go. Madagascar than a truth that hurts. Czech Republic than a relative far away. Korea than with a fence. Czech Republic
Screening Log Screening Number ID Date Patient Initials Source of identification (eg. Ortho clinic, DXA) Patient meets eligibility Y/N If not, reason Study info given/sent Patient willing to participate Y/N If no, reason Appt. date Comments